Arthur F. Golden

CIK: 0001023260

Transaction Breakdown

Open Market Buys (P)3 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)1 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TTRX

Turn Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

TTRX
Turn Therapeutics Inc.
Jun 4, 2026
Award(A)
Stock option (right to buy)
Direct
89.6K shares-
TTRX
Turn Therapeutics Inc.
Apr 2, 2026
Gift(G)
Direct
300K shares-
TTRX
Turn Therapeutics Inc.
Nov 24, 2025
Purchase(P)
Direct
9.9K shares at avg. $3.44$34K
TTRX
Turn Therapeutics Inc.
Nov 21, 2025
Purchase(P)
Direct
20.5K shares at avg. $2.87$59K
TTRX
Turn Therapeutics Inc.
Oct 23, 2025
Purchase(P)
Direct
20.2K shares at avg. $4.95$100K
TTRX
Turn Therapeutics Inc.
Oct 8, 2025
Award(A)
Direct
10K shares-

		Type	Shares	Price		Ownership
Jun 4, 2026	TTRX Turn Therapeutics Inc.	Award(A) Stock option (right to buy)	89,584	-	-	Direct
Apr 2, 2026	TTRX Turn Therapeutics Inc.	Gift(G)	300,000	-	$0	Direct
Nov 24, 2025	TTRX Turn Therapeutics Inc.	Purchase(P)	9,868	$3.44	$33,946	Direct
Nov 21, 2025	TTRX Turn Therapeutics Inc.	Purchase(P)	20,532	$2.87	$58,927	Direct
Oct 23, 2025	TTRX Turn Therapeutics Inc.	Purchase(P)	20,202	$4.95	$100,000	Direct
Oct 8, 2025	TTRX Turn Therapeutics Inc.	Award(A)	10,000	-	-	Direct

1-6 of 6 transactions

About GOLDEN ARTHUR F

GOLDEN ARTHUR F (SEC CIK 0001023260) files insider reports with the SEC as Director of Turn Therapeutics Inc. (TTRX).

Signal8 holds 7 ownership filings by GOLDEN ARTHUR F (1 Form 3, 6 Form 4), filed between Oct 7, 2025 and Jun 8, 2026. Those filings report 6 transactions, from Oct 8, 2025 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on GOLDEN ARTHUR F's filings is in WESTLAKE VILLAGE, CA.

Recent filings by GOLDEN ARTHUR F

Jun 4, 2026: Grant or award of TTRX derivative securities (Form 4, code A).
Apr 2, 2026: Gift of TTRX shares (Form 4, code G).
Nov 24, 2025: Open-market purchase of TTRX shares (Form 4, code P).
Nov 21, 2025: Open-market purchase of TTRX shares (Form 4, code P).
Oct 23, 2025: Open-market purchase of TTRX shares (Form 4, code P).

Other insiders filing for Turn Therapeutics Inc. (TTRX)

Dewhurst Martin William, Director
Gengos Andrew, Director
Kester Kent Edward, Director
Burnam Bradley Evan, Chief Executive Officer
Chaudhary Zuraiz
Chesed Abraham, Officer

How to read Form 4 transaction codes